{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T07:05:46Z","timestamp":1760598346764,"version":"3.40.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,17]]},"DOI":"10.7759\/cureus.84280","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T13:50:15Z","timestamp":1747489815000},"source":"Crossref","is-referenced-by-count":1,"title":["A Multicentre Clinical Trial Protocol of Shuganjieyu Capsules Combined With Fluoxetine in the Treatment of Depression"],"prefix":"10.7759","author":[{"given":"Ji-tao","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-mei","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin-lin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-jian","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-fen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan-zhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-qin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-ai","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian-mei","family":"Si","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31948-2","article-title":"Depression","volume":"392","author":"Malhi GS","year":"2018","unstructured":"Malhi GS, Mann JJ. Depression. Lancet. 2018, 392:2299-312. 10.1016\/S0140-6736(18)31948-2","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpr.2018.06.008","article-title":"Depression: a cognitive perspective","volume":"69","author":"LeMoult J","year":"2019","unstructured":"LeMoult J, Gotlib IH. Depression: a cognitive perspective. Clin Psychol Rev. 2019, 69:51-66. 10.1016\/j.cpr.2018.06.008","journal-title":"Clin Psychol Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02141-3","article-title":"","volume":"399","author":"Herrman H","year":"2022","unstructured":"Herrman H, Patel V, Kieling C, et al.. Time for united action on depression: a Lancet-World Psychiatric Association Commission. 2022, 399:957-1022. 10.1016\/S0140-6736(21)02141-3","journal-title":"Time for united action on depression: a Lancet-World Psychiatric Association Commission"},{"key":"ref4","unstructured":"Depressive disorder (depression) |WHO. (2023). Accessed. 31 Mar 2023: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/depression."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2017.05.003","article-title":"A systematic review and meta-regression of the prevalence and incidence of perinatal depression","volume":"219","author":"Woody CA","year":"2017","unstructured":"Woody CA, Ferrari AJ, Siskind DJ, Whiteford HA, Harris MG. A systematic review and meta-regression of the prevalence and incidence of perinatal depression. J Affect Disord. 2017, 219:86-92. 10.1016\/j.jad.2017.05.003","journal-title":"J Affect Disord"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20701","article-title":"A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression","volume":"19","author":"Cuijpers P","year":"2020","unstructured":"Cuijpers P, Noma H, Karyotaki E, Vinkers CH, Cipriani A, Furukawa TA. A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry. 2020, 19:92-107. 10.1002\/wps.20701","journal-title":"World Psychiatry"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31140-0","article-title":"Cost and outcome of behavioural activation versus cognitive behavioural therapy for depression (COBRA): a randomised, controlled, non-inferiority trial","volume":"388","author":"Richards DA","year":"2016","unstructured":"Richards DA, Ekers D, McMillan D, et al.. Cost and outcome of behavioural activation versus cognitive behavioural therapy for depression (COBRA): a randomised, controlled, non-inferiority trial. Lancet. 2016, 388:871-80. 10.1016\/S0140-6736(16)31140-0","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.115.164715","article-title":"Transcranial direct current stimulation for acute major depressive episodes: meta-analysis of individual patient data","volume":"208","author":"Brunoni AR","year":"2016","unstructured":"Brunoni AR, Moffa AH, Fregni F, et al.. Transcranial direct current stimulation for acute major depressive episodes: meta-analysis of individual patient data. Br J Psychiatry. 2016, 208:522-31. 10.1192\/bjp.bp.115.164715","journal-title":"Br J Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02080-3","article-title":"Novel and emerging treatments for major depression","volume":"401","author":"Marwaha S","year":"2023","unstructured":"Marwaha S, Palmer E, Suppes T, Cons E, Young AH, Upthegrove R. Novel and emerging treatments for major depression. Lancet. 2023, 401:141-53. 10.1016\/S0140-6736(22)02080-3","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21069","article-title":"Cognitive behavior therapy vs. control conditions, other psychotherapies, pharmacotherapies and combined treatment for depression: a comprehensive meta-analysis including 409 trials with 52,702 patients","volume":"22","author":"Cuijpers P","year":"2023","unstructured":"Cuijpers P, Miguel C, Harrer M, Plessen CY, Ciharova M, Ebert D, Karyotaki E. Cognitive behavior therapy vs. control conditions, other psychotherapies, pharmacotherapies and combined treatment for depression: a comprehensive meta-analysis including 409 trials with 52,702 patients. World Psychiatry. 2023, 22:105-15. 10.1002\/wps.21069","journal-title":"World Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/07067437241245384","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults: R\u00e9seau canadien pour les traitements de l'humeur et de l'anxi\u00e9t\u00e9 (CANMAT) 2023 : Mise \u00e0 jour des lignes directrices cliniques pour la prise en charge du trouble d\u00e9pressif majeur chez les adultes","volume":"69","author":"Lam RW","year":"2024","unstructured":"Lam RW, Kennedy SH, Adams C, et al.. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults: R\u00e9seau canadien pour les traitements de l'humeur et de l'anxi\u00e9t\u00e9 (CANMAT) 2023 : Mise \u00e0 jour des lignes directrices cliniques pour la prise en charge du trouble d\u00e9pressif majeur chez les adultes. Can J Psychiatry. 2024, 69:641-87. 10.1177\/07067437241245384","journal-title":"Can J Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush AJ","year":"2006","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, et al.. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006, 163:1905-17. 10.1176\/ajp.2006.163.11.1905","journal-title":"Am J Psychiatry"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291709006011","article-title":"Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report","volume":"40","author":"Nierenberg AA","year":"2010","unstructured":"Nierenberg AA, Husain MM, Trivedi MH, et al.. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med. 2010, 40:41-50. 10.1017\/S0033291709006011","journal-title":"Psychol Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/gpsych-2024-101747","article-title":"Guidelines for the diagnosis and treatment of depressive disorders by integrating Chinese and Western medicine (English edition)","volume":"10;38(1)","author":"Lanying Liu","year":"2025","unstructured":"Lanying Liu, Jianjun Wang, Wei Li, et al.. Guidelines for the diagnosis and treatment of depressive disorders by integrating Chinese and Western medicine (English edition). Gen Psychiatr. 2025 Feb , 10;38(1):e101747. 10.1136\/gpsych-2024-101747","journal-title":"Gen Psychiatr"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1407869","article-title":"Pathogenesis of depression and the potential for traditional Chinese medicine treatment","volume":"25:15:1407869","author":"Weixing Ding","year":"2024","unstructured":"Weixing Ding, Lulu Wang, Lei Li, et al.. Pathogenesis of depression and the potential for traditional Chinese medicine treatment. Front Pharmacol. 2024 Jun , 25:15:1407869:eCollection 2024. 10.3389\/fphar.2024.1407869","journal-title":"Front Pharmacol"},{"key":"ref16","article-title":"Efficacy and safety of the Chinese herbal medicine shuganjieyu with and without adjunctive repetitive transcranial magnetic stimulation (rTMS) for geriatric depression: a randomized controlled trial","volume":"27","author":"Xie M","year":"2015","unstructured":"Xie M, Jiang W, Yang H. Efficacy and safety of the Chinese herbal medicine shuganjieyu with and without adjunctive repetitive transcranial magnetic stimulation (rTMS) for geriatric depression: a randomized controlled trial. Shanghai Arch Psychiatry. 2015, 27:103-10.","journal-title":"Shanghai Arch Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.11669\/cpj.2021.01.008","article-title":"HPLC-MS\/MS method for determination of the concentration of main active ingredients in the extracts of Acanthopanax senticosus and Hypericum perforatum L. and their pharmacokinetics in rats","volume":"56","author":"Zhu Y","year":"2021","unstructured":"Zhu Y, Han XM, Ke X, et al.. HPLC-MS\/MS method for determination of the concentration of main active ingredients in the extracts of Acanthopanax senticosus and Hypericum perforatum L. and their pharmacokinetics in rats. Chin Pharm J. 2021, 56:46-53. 10.11669\/cpj.2021.01.008","journal-title":"Chin Pharm J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.828595","article-title":"Antidepressant Shugan Jieyu capsule alters gut microbiota and intestinal microbiome function in rats with chronic unpredictable mild stress -induced depression","volume":"13","author":"Tan J","year":"2022","unstructured":"Tan J, Li X, Zhu Y, Sullivan MA, Deng B, Zhai X, Lu Y. Antidepressant Shugan Jieyu capsule alters gut microbiota and intestinal microbiome function in rats with chronic unpredictable mild stress -induced depression. Front Pharmacol. 2022, 13:828595. 10.3389\/fphar.2022.828595","journal-title":"Front Pharmacol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/13607863.2014.899975","article-title":"Shuganjieyu capsule for major depressive disorder (MDD) in adults: a systematic review","volume":"18","author":"Zhang X","year":"2014","unstructured":"Zhang X, Kang D, Zhang L, Peng L. Shuganjieyu capsule for major depressive disorder (MDD) in adults: a systematic review. Aging Ment Health. 2014, 18:941-53. 10.1080\/13607863.2014.899975","journal-title":"Aging Ment Health"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3791\/64660","article-title":"Meta-analysis of the effectiveness and safety of Shugan Jieyu capsules for the treatment of insomnia","volume":"17","author":"Wang W","year":"2023","unstructured":"Wang W, Du P, Zhong LL, et al.. Meta-analysis of the effectiveness and safety of Shugan Jieyu capsules for the treatment of insomnia. J Vis Exp. 2023 Feb,  17:10.3791\/64660","journal-title":"J Vis Exp"},{"key":"ref21","article-title":"Interpretation of the guideline for prevention and treatment of depression in China (Second Edition)[M]","author":"Li LJ","year":"2015","unstructured":"Li LJ, Ma X. Interpretation of the guideline for prevention and treatment of depression in China (Second Edition)[M]. Beijing: China Medical Electronic Audio-Visual Publishing House (ed): 2015."},{"key":"ref22","unstructured":"Guideline for Good Clinical Practice E6(R3). (2025). Accessed. 6 January : https:\/\/database.ich.org\/sites\/default\/files\/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2016.12.013","article-title":"The effect of treatment as usual on major depressive disorder: a meta-analysis","volume":"210","author":"Kolovos S","year":"2017","unstructured":"Kolovos S, van Tulder MW, Cuijpers P, Prigent A, Chevreul K, Riper H, Bosmans JE. The effect of treatment as usual on major depressive disorder: a meta-analysis. J Affect Disord. 2017, 210:72-81. 10.1016\/j.jad.2016.12.013","journal-title":"J Affect Disord"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1590\/1516-4446-2020-0935","article-title":"How can we improve antidepressant adherence in the management of depression? A targeted review and 10 clinical recommendations","volume":"43(2)","author":"Marco Solmi","year":"2021","unstructured":"Marco Solmi, Alessandro Miola, Giovanni Croatto, et al.. How can we improve antidepressant adherence in the management of depression? A targeted review and 10 clinical recommendations. Braz J Psychiatry. 2021 Mar-Apr, 43(2):189-202. 10.1590\/1516-4446-2020-0935","journal-title":"Braz J Psychiatry"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2019.04.104","article-title":"Guidelines for the diagnosis and treatment of depressive disorders in China: the second edition","volume":"15:253","author":"Yuan Feng","year":"2019","unstructured":"Yuan Feng, Le Xiao, Wei-Wei Wang, et al.. Guidelines for the diagnosis and treatment of depressive disorders in China: the second edition. J Affect Disord. 2019 Jun, 15:253:352-356. 10.1016\/j.jad.2019.04.104","journal-title":"J Affect Disord"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/354671-a-multicentre-clinical-trial-protocol-of-shuganjieyu-capsules-combined-with-fluoxetine-in-the-treatment-of-depression","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T13:50:21Z","timestamp":1747489821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/354671-a-multicentre-clinical-trial-protocol-of-shuganjieyu-capsules-combined-with-fluoxetine-in-the-treatment-of-depression"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,17]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.84280","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,17]]}}}